{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:53:11Z","timestamp":1793307191644,"version":"4.5.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Chronic pruritus (CP) is among the most distressing symptoms and has a complex pathophysiology. This review aims to describe the mediators and mechanisms of neuroimmune crosstalk\u2014a term referring the bidirectional interactions between the nervous and immune systems that underly itch pathogenesis and chronicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Type 2 cytokines (IL-4, IL-13, IL-31) directly activate pruriceptive neurons, resulting in itch sensation and nerve fiber sensitization via TRPV1\/TRPA1, whereas keratinocyte-derived alarmins (TSLP and IL-33) amplify neural activation. Periostin, an emerging downstream mediator, binds integrin \u03b1V\u03b23 on neurons and induces macrophage IL-31 release, representing a link between immune and neural pathways. BNP, another emerging mediator that is co-expressed with IL-31, facilitates itch signaling in the spinal cord and induces keratinocyte production of itch mediators, highlighting its integral role in neuroimmune signaling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>CP arises from a complex interplay between the immune system, sensory neurons, and keratinocytes. The success of therapeutic advances targeting cytokines, neuropeptides, and their receptors in recent years have confirmed the importance of understanding these complex underlying networks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11882-026-01255-8","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T11:34:31Z","timestamp":1771500871000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cross-Talk between Neurons and Immune Cells in Pruritus: from Mechanisms To Medicines"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2332-3557","authenticated-orcid":false,"given":"Nicole","family":"Khalil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3983-6687","authenticated-orcid":false,"given":"Tomer","family":"Kagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6303-1822","authenticated-orcid":false,"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"issue":"24","key":"1255_CR1","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1001\/jama.2024.4899","volume":"331","author":"DC Butler","year":"2024","unstructured":"Butler DC, Berger T, Elmariah S, Kim B, Chisolm S, Kwatra SG, et al. Chronic Pruritus: Rev Jama. 2024;331(24):2114\u201324. https:\/\/doi.org\/10.1001\/jama.2024.4899.","journal-title":"Chronic Pruritus: Rev Jama"},{"issue":"2","key":"1255_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/jdv.15973","volume":"34","author":"G Yosipovitch","year":"2020","unstructured":"Yosipovitch G, Berger T, Fassett MS. Neuroimmune interactions in chronic itch of atopic dermatitis. J Eur Acad Dermatol Venereol. 2020;34(2):239\u201350. https:\/\/doi.org\/10.1111\/jdv.15973.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1255_CR3","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.jaci.2022.03.010","volume":"149","author":"M Steinhoff","year":"2022","unstructured":"Steinhoff M, Ahmad F, Pandey A, Datsi A, AlHammadi A, Al-Khawaga S, et al. Neuroimmune communication regulating pruritus in atopic dermatitis. J Allergy Clin Immunol. 2022;149(6):1875\u201398. https:\/\/doi.org\/10.1016\/j.jaci.2022.03.010.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1255_CR4","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.jaci.2018.09.005","volume":"142","author":"G Yosipovitch","year":"2018","unstructured":"Yosipovitch G, Rosen JD, Hashimoto T, Itch. From mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol. 2018;142(5):1375\u201390. https:\/\/doi.org\/10.1016\/j.jaci.2018.09.005.","journal-title":"J Allergy Clin Immunol"},{"key":"1255_CR5","doi-asserted-by":"publisher","first-page":"1272230","DOI":"10.3389\/fnmol.2023.1272230","volume":"16","author":"O Mahmoud","year":"2023","unstructured":"Mahmoud O, Oladipo O, Mahmoud RH, Yosipovitch G. Itch: from the skin to the brain - peripheral and central neural sensitization in chronic itch. Front Mol Neurosci. 2023;16:1272230. https:\/\/doi.org\/10.3389\/fnmol.2023.1272230.","journal-title":"Front Mol Neurosci"},{"key":"1255_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.05.011","author":"MK Jha","year":"2025","unstructured":"Jha MK, Han Y, Liu Z, Hara Y, Langohr IM, Morel C, et al. Type 2 cytokines pleiotropically modulate sensory nerve architecture and neuroimmune interactions to mediate itch. J Allergy Clin Immunol. 2025. https:\/\/doi.org\/10.1016\/j.jaci.2025.05.011.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1255_CR7","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1111\/all.15699","volume":"78","author":"X Liu","year":"2023","unstructured":"Liu X, Wang Y, Zeng Y, Wang D, Wen Y, Fan L, et al. Microglia-neuron interactions promote chronic itch via the NLRP3-IL-1\u03b2-GRPR axis. Allergy. 2023;78(6):1570\u201384. https:\/\/doi.org\/10.1111\/all.15699.","journal-title":"Allergy"},{"issue":"10","key":"1255_CR8","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.jid.2021.03.009","volume":"141","author":"T Hashimoto","year":"2021","unstructured":"Hashimoto T, Mishra SK, Olivry T, Yosipovitch G. Periostin, an emerging player in itch sensation. J Invest Dermatol. 2021;141(10):2338\u201343. https:\/\/doi.org\/10.1016\/j.jid.2021.03.009.","journal-title":"J Invest Dermatol"},{"issue":"10","key":"1255_CR9","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1016\/j.jid.2024.02.026","volume":"144","author":"LA Nattkemper","year":"2024","unstructured":"Nattkemper LA, Kim BS, Yap QV, Hoon MA, Mishra SK, Yosipovitch G. Increased systemic levels of centrally acting B-Type natriuretic peptide are associated with chronic itch of different types. J Invest Dermatol. 2024;144(10):2267\u201372. https:\/\/doi.org\/10.1016\/j.jid.2024.02.026.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1255_CR10","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.neuron.2018.03.023","volume":"98","author":"X Dong","year":"2018","unstructured":"Dong X, Dong X. Peripheral and central mechanisms of itch. Neuron. 2018;98(3):482\u201394. https:\/\/doi.org\/10.1016\/j.neuron.2018.03.023.","journal-title":"Neuron"},{"issue":"4","key":"1255_CR11","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1016\/j.neuroimage.2011.10.099","volume":"59","author":"AD Papoiu","year":"2012","unstructured":"Papoiu AD, Coghill RC, Kraft RA, Wang H, Yosipovitch G. A Tale of two itches. Common features and notable differences in brain activation evoked by cowhage and Histamine induced itch. NeuroImage. 2012;59(4):3611\u201323. https:\/\/doi.org\/10.1016\/j.neuroimage.2011.10.099.","journal-title":"NeuroImage"},{"issue":"3","key":"1255_CR12","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/all.15090","volume":"77","author":"T Zuberbier","year":"2022","unstructured":"Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI\/GA\u00b2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734\u201366. https:\/\/doi.org\/10.1111\/all.15090.","journal-title":"Allergy"},{"issue":"1","key":"1255_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd2465","volume":"7","author":"RL Thurmond","year":"2008","unstructured":"Thurmond RL, Gelfand EW, Dunford PJ. The role of Histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov. 2008;7(1):41\u201353. https:\/\/doi.org\/10.1038\/nrd2465.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"1255_CR14","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1523\/jneurosci.4643-06.2007","volume":"27","author":"WS Shim","year":"2007","unstructured":"Shim WS, Tak MH, Lee MH, Kim M, Kim M, Koo JY, et al. TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase. J Neurosci. 2007;27(9):2331\u20137. https:\/\/doi.org\/10.1523\/jneurosci.4643-06.2007.","journal-title":"J Neurosci"},{"issue":"27","key":"1255_CR15","doi-asserted-by":"publisher","first-page":"11330","DOI":"10.1073\/pnas.0905605106","volume":"106","author":"N Imamachi","year":"2009","unstructured":"Imamachi N, Park GH, Lee H, Anderson DJ, Simon MI, Basbaum AI, et al. TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms. Proc Natl Acad Sci U S A. 2009;106(27):11330\u20135. https:\/\/doi.org\/10.1073\/pnas.0905605106.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"1255_CR16","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1610020.","journal-title":"N Engl J Med"},{"issue":"7","key":"1255_CR17","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.cell.2009.11.034","volume":"139","author":"Q Liu","year":"2009","unstructured":"Liu Q, Tang Z, Surdenikova L, Kim S, Patel KN, Kim A, et al. Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus. Cell. 2009;139(7):1353\u201365. https:\/\/doi.org\/10.1016\/j.cell.2009.11.034.","journal-title":"Cell"},{"issue":"5","key":"1255_CR18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nn.2789","volume":"14","author":"SR Wilson","year":"2011","unstructured":"Wilson SR, Gerhold KA, Bifolck-Fisher A, Liu Q, Patel KN, Dong X, et al. TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptor-mediated itch. Nat Neurosci. 2011;14(5):595\u2013602. https:\/\/doi.org\/10.1038\/nn.2789.","journal-title":"Nat Neurosci"},{"issue":"11","key":"1255_CR19","doi-asserted-by":"publisher","first-page":"5371","DOI":"10.4049\/jimmunol.1300300","volume":"191","author":"MH Oh","year":"2013","unstructured":"Oh MH, Oh SY, Lu J, Lou H, Myers AC, Zhu Z, et al. TRPA1-dependent pruritus in IL-13-induced chronic atopic dermatitis. J Immunol. 2013;191(11):5371\u201382. https:\/\/doi.org\/10.4049\/jimmunol.1300300.","journal-title":"J Immunol"},{"issue":"2","key":"1255_CR20","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jaci.2016.12.980","volume":"140","author":"E Azimi","year":"2017","unstructured":"Azimi E, Reddy VB, Pereira PJS, Talbot S, Woolf CJ, Lerner EA. Substance P activates Mas-related G protein-coupled receptors to induce itch. J Allergy Clin Immunol. 2017;140(2):447\u2013e533. https:\/\/doi.org\/10.1016\/j.jaci.2016.12.980.","journal-title":"J Allergy Clin Immunol"},{"key":"1255_CR21","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3389\/fphys.2018.01249","volume":"9","author":"Z Kee","year":"2018","unstructured":"Kee Z, Kodji X, Brain SD. The role of calcitonin gene related peptide (CGRP) in neurogenic vasodilation and its cardioprotective effects. Front Physiol. 2018;9:1249. https:\/\/doi.org\/10.3389\/fphys.2018.01249.","journal-title":"Front Physiol"},{"issue":"6135","key":"1255_CR22","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1126\/science.1233765","volume":"340","author":"SK Mishra","year":"2013","unstructured":"Mishra SK, Hoon MA. The cells and circuitry for itch responses in mice. Science. 2013;340(6135):968\u201371. https:\/\/doi.org\/10.1126\/science.1233765.","journal-title":"Science"},{"key":"1255_CR23","doi-asserted-by":"publisher","unstructured":"Meng QT, Liu XY, Liu XT, Liu J, Munanairi A, Barry DM, et al. BNP facilitates NMB-encoded histaminergic itch via NPRC-NMBR crosstalk. Elife. 2021;10. https:\/\/doi.org\/10.7554\/eLife.71689.","DOI":"10.7554\/eLife.71689"},{"issue":"7154","key":"1255_CR24","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/nature06029","volume":"448","author":"YG Sun","year":"2007","unstructured":"Sun YG, Chen ZF. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature. 2007;448(7154):700\u20133. https:\/\/doi.org\/10.1038\/nature06029.","journal-title":"Nature"},{"issue":"7","key":"1255_CR25","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1097\/j.pain.0000000000001220","volume":"159","author":"HH Andersen","year":"2018","unstructured":"Andersen HH, Akiyama T, Nattkemper LA, van Laarhoven A, Elberling J, Yosipovitch G, et al. Alloknesis and hyperknesis-mechanisms, assessment methodology, and clinical implications of itch sensitization. Pain. 2018;159(7):1185\u201397. https:\/\/doi.org\/10.1097\/j.pain.0000000000001220.","journal-title":"Pain"},{"issue":"5","key":"1255_CR26","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.anai.2017.12.025","volume":"120","author":"HH Andersen","year":"2018","unstructured":"Andersen HH, Yosipovitch G, Arendt-Nielsen L. Pain inhibits itch, but not in atopic dermatitis? Annals of allergy. Asthma Immunol. 2018;120(5):548\u20139. https:\/\/doi.org\/10.1016\/j.anai.2017.12.025.","journal-title":"Asthma Immunol"},{"issue":"10","key":"1255_CR27","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/j.pain.2014.08.013","volume":"155","author":"W Kallenborn-Gerhardt","year":"2014","unstructured":"Kallenborn-Gerhardt W, Hohmann SW, Syhr KM, Schr\u00f6der K, Sisignano M, Weigert A, et al. Nox2-dependent signaling between macrophages and sensory neurons contributes to neuropathic pain hypersensitivity. Pain. 2014;155(10):2161\u201370. https:\/\/doi.org\/10.1016\/j.pain.2014.08.013.","journal-title":"Pain"},{"key":"1255_CR28","doi-asserted-by":"publisher","first-page":"825427","DOI":"10.3389\/fcimb.2021.825427","volume":"11","author":"L Willen","year":"2021","unstructured":"Willen L, Ekinci E, Cuypers L, Theeten H, Desmet S. Infant Pneumococcal carriage in Belgium not affected by COVID-19 containment measures. Front Cell Infect Microbiol. 2021;11:825427. https:\/\/doi.org\/10.3389\/fcimb.2021.825427.","journal-title":"Front Cell Infect Microbiol"},{"key":"1255_CR29","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.nano.2019.02.006","volume":"17","author":"KK Chenab","year":"2019","unstructured":"Chenab KK, Eivazzadeh-Keihan R, Maleki A, Pashazadeh-Panahi P, Hamblin MR, Mokhtarzadeh A. Biomedical applications of nanoflares: targeted intracellular fluorescence probes. Nanomedicine. 2019;17:342\u201358. https:\/\/doi.org\/10.1016\/j.nano.2019.02.006.","journal-title":"Nanomedicine"},{"issue":"1","key":"1255_CR30","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","volume":"171","author":"LK Oetjen","year":"2017","unstructured":"Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ, et al. Sensory neurons Co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217\u2013e2813. https:\/\/doi.org\/10.1016\/j.cell.2017.08.006.","journal-title":"Cell"},{"issue":"2","key":"1255_CR31","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","volume":"133","author":"F Cevikbas","year":"2014","unstructured":"Cevikbas F, Wang X, Akiyama T, Kempkes C, Savinko T, Antal A, et al. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1. J Allergy Clin Immunol. 2014;133(2):448\u201360. https:\/\/doi.org\/10.1016\/j.jaci.2013.10.048.","journal-title":"J Allergy Clin Immunol"},{"issue":"619","key":"1255_CR32","doi-asserted-by":"publisher","first-page":"eabe3037","DOI":"10.1126\/scitranslmed.abe3037","volume":"13","author":"PY Tseng","year":"2021","unstructured":"Tseng PY, Hoon MA. Oncostatin M can sensitize sensory neurons in inflammatory pruritus. Sci Transl Med. 2021;13(619):eabe3037.","journal-title":"Sci Transl Med"},{"issue":"5","key":"1255_CR33","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/j.jaci.2017.12.1002","volume":"141","author":"J Meng","year":"2018","unstructured":"Meng J, Moriyama M, Feld M, Buddenkotte J, Buhl T, Sz\u00f6ll\u00f6si A, et al. New mechanism underlying IL-31-induced atopic dermatitis. J Allergy Clin Immunol. 2018;141(5):1677\u2013e898. https:\/\/doi.org\/10.1016\/j.jaci.2017.12.1002.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1255_CR34","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.jid.2019.09.012","volume":"140","author":"T Hashimoto","year":"2020","unstructured":"Hashimoto T, Kursewicz CD, Fayne RA, Nanda S, Shah SM, Nattkemper L, et al. Mechanisms of itch in stasis dermatitis: significant role of IL-31 from macrophages. J Invest Dermatol. 2020;140(4):850\u2013e93. https:\/\/doi.org\/10.1016\/j.jid.2019.09.012.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1255_CR35","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jaci.2022.11.009","volume":"151","author":"T Hashimoto","year":"2023","unstructured":"Hashimoto T, Yokozeki H, Karasuyama H, Satoh T. IL-31-generating network in atopic dermatitis comprising macrophages, basophils, thymic stromal lymphopoietin, and Periostin. J Allergy Clin Immunol. 2023;151(3):737\u2013e466. https:\/\/doi.org\/10.1016\/j.jaci.2022.11.009.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1255_CR36","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.jmb.2011.06.005","volume":"411","author":"C Kosiol","year":"2011","unstructured":"Kosiol C, Goldman N. Markovian and non-Markovian protein sequence evolution: aggregated Markov process models. J Mol Biol. 2011;411(4):910\u201323. https:\/\/doi.org\/10.1016\/j.jmb.2011.06.005.","journal-title":"J Mol Biol"},{"issue":"3","key":"1255_CR37","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s12016-015-8488-5","volume":"51","author":"NK Mollanazar","year":"2016","unstructured":"Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: getting the itch out? Clin Rev Allergy Immunol. 2016;51(3):263\u201392. https:\/\/doi.org\/10.1007\/s12016-015-8488-5.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"1255_CR38","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.cell.2013.08.057","volume":"155","author":"SR Wilson","year":"2013","unstructured":"Wilson SR, Th\u00e9 L, Batia LM, Beattie K, Katibah GE, McClain SP, et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell. 2013;155(2):285\u201395. https:\/\/doi.org\/10.1016\/j.cell.2013.08.057.","journal-title":"Cell"},{"key":"1255_CR39","doi-asserted-by":"publisher","unstructured":"Garcovich S, Maurelli M, Gisondi P, Peris K, Yosipovitch G, Girolomoni G. Pruritus as a distinctive feature of type 2 inflammation. Vaccines (Basel). 2021;9(3). https:\/\/doi.org\/10.3390\/vaccines9030303.","DOI":"10.3390\/vaccines9030303"},{"key":"1255_CR40","doi-asserted-by":"crossref","unstructured":"Nattkemper LA, Tey HL, Valdes-Rodriguez R, Lee H, Mollanazar NK, Albornoz C, et al.The Genetics of Chronic Itch: Gene Expression in the Skin of Patients with Atopic Dermatitis and Psoriasis with Severe\u00a0Itch. Journal of Investigative Dermatology.2018;138(6):1311-7. doi: 10.1016\/j.jid.2017.12.029.","DOI":"10.1016\/j.jid.2017.12.029"},{"issue":"1","key":"1255_CR41","doi-asserted-by":"publisher","first-page":"111933","DOI":"10.1016\/j.celrep.2022.111933","volume":"42","author":"S Nunomura","year":"2023","unstructured":"Nunomura S, Uta D, Kitajima I, Nanri Y, Matsuda K, Ejiri N, et al. Periostin activates distinct modules of inflammation and itching downstream of the type 2 inflammation pathway. Cell Rep. 2023;42(1):111933. https:\/\/doi.org\/10.1016\/j.celrep.2022.111933.","journal-title":"Cell Rep"},{"issue":"12","key":"1255_CR42","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/exd.14014","volume":"28","author":"C Nakashima","year":"2019","unstructured":"Nakashima C, Ishida Y, Kitoh A, Otsuka A, Kabashima K. Interaction of peripheral nerves and mast cells, eosinophils, and basophils in the development of pruritus. Exp Dermatol. 2019;28(12):1405\u201311. https:\/\/doi.org\/10.1111\/exd.14014.","journal-title":"Exp Dermatol"},{"key":"1255_CR43","doi-asserted-by":"publisher","first-page":"745658","DOI":"10.3389\/fphar.2022.745658","volume":"13","author":"AG Sz\u00f6ll\u0151si","year":"2022","unstructured":"Sz\u00f6ll\u0151si AG, Ol\u00e1h A, Lisztes E, Griger Z, T\u00f3th BI. Pruritus: A sensory symptom generated in cutaneous Immuno-Neuronal crosstalk. Front Pharmacol. 2022;13:745658. https:\/\/doi.org\/10.3389\/fphar.2022.745658.","journal-title":"Front Pharmacol"},{"key":"1255_CR44","doi-asserted-by":"publisher","first-page":"1258823","DOI":"10.3389\/fnmol.2023.1258823","volume":"16","author":"MR Mack","year":"2023","unstructured":"Mack MR, Miron Y, Chen F, Miller PE, Zhang A, Korotzer A, et al. Type 2 cytokines sensitize human sensory neurons to itch-associated stimuli. Front Mol Neurosci. 2023;16:1258823. https:\/\/doi.org\/10.3389\/fnmol.2023.1258823.","journal-title":"Front Mol Neurosci"},{"key":"1255_CR45","doi-asserted-by":"publisher","unstructured":"Tomaszewska K, S\u0142odka A, Tarkowski B, Zalewska-Janowska A. Neuro-Immuno-Psychological aspects of chronic urticaria. J Clin Med. 2023;12(9). https:\/\/doi.org\/10.3390\/jcm12093134.","DOI":"10.3390\/jcm12093134"},{"key":"1255_CR46","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000003742","author":"PY Tseng","year":"2025","unstructured":"Tseng PY, Liew HL, Ringkamp M, Nagao K, Hoon MA. Upregulated natriuretic peptide B expression as a hallmark of chronic itch. Pain. 2025. https:\/\/doi.org\/10.1097\/j.pain.0000000000003742.","journal-title":"Pain"},{"key":"1255_CR47","doi-asserted-by":"publisher","first-page":"155664","DOI":"10.1016\/j.cyto.2021.155664","volume":"148","author":"S Nakajima","year":"2021","unstructured":"Nakajima S, Tie D, Nomura T, Kabashima K. Novel pathogenesis of atopic dermatitis from the view of cytokines in mice and humans. Cytokine. 2021;148:155664. https:\/\/doi.org\/10.1016\/j.cyto.2021.155664.","journal-title":"Cytokine"},{"issue":"3","key":"1255_CR48","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40257-023-00838-9","volume":"25","author":"M Croft","year":"2024","unstructured":"Croft M, Esfandiari E, Chong C, Hsu H, Kabashima K, Kricorian G, et al. OX40 in the pathogenesis of atopic Dermatitis-A new therapeutic target. Am J Clin Dermatol. 2024;25(3):447\u201361. https:\/\/doi.org\/10.1007\/s40257-023-00838-9.","journal-title":"Am J Clin Dermatol"},{"key":"1255_CR49","doi-asserted-by":"publisher","unstructured":"Wiegmann H, Renkhold L, Zeidler C, Agelopoulos K, St\u00e4nder S. Interleukin profiling in atopic dermatitis and chronic nodular prurigo. Int J Mol Sci. 2024;25(15). https:\/\/doi.org\/10.3390\/ijms25158445.","DOI":"10.3390\/ijms25158445"},{"issue":"6","key":"1255_CR50","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/exd.14279","volume":"30","author":"T Hashimoto","year":"2021","unstructured":"Hashimoto T, Nattkemper LA, Kim HS, Kursewicz CD, Fowler E, Shah SM, et al. Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, Oncostatin M, IL-31 receptor alpha and Oncostatin M receptor beta. Exp Dermatol. 2021;30(6):804\u201310. https:\/\/doi.org\/10.1111\/exd.14279.","journal-title":"Exp Dermatol"},{"issue":"10","key":"1255_CR51","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1111\/all.14791","volume":"76","author":"A Datsi","year":"2021","unstructured":"Datsi A, Steinhoff M, Ahmad F, Alam M, Buddenkotte J. Interleukin-31: the itchy cytokine in inflammation and therapy. Allergy. 2021;76(10):2982\u201397. https:\/\/doi.org\/10.1111\/all.14791.","journal-title":"Allergy"},{"issue":"8","key":"1255_CR52","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa1908316","volume":"382","author":"S St\u00e4nder","year":"2020","unstructured":"St\u00e4nder S, Yosipovitch G, Legat FJ, Lacour JP, Paul C, Narbutt J, et al. Trial of Nemolizumab in Moderate-to-Severe prurigo nodularis. N Engl J Med. 2020;382(8):706\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1908316.","journal-title":"N Engl J Med"},{"issue":"9","key":"1255_CR53","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1001\/jamadermatol.2023.2609","volume":"159","author":"J Deng","year":"2023","unstructured":"Deng J, Liao V, Parthasarathy V, Cornman HL, Kambala A, Kwatra MM, et al. Modulation of neuroimmune and epithelial dysregulation in patients with moderate to severe prurigo nodularis treated with Nemolizumab. JAMA Dermatol. 2023;159(9):977\u201385. https:\/\/doi.org\/10.1001\/jamadermatol.2023.2609.","journal-title":"JAMA Dermatol"},{"issue":"17","key":"1255_CR54","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1001\/jama.2024.15568","volume":"332","author":"P Kolkhir","year":"2024","unstructured":"Kolkhir P, Bonnekoh H, Metz M, Maurer M. Chronic spontaneous urticaria: A review. JAMA. 2024;332(17):1464\u201377. https:\/\/doi.org\/10.1001\/jama.2024.15568.","journal-title":"JAMA"},{"issue":"9","key":"1255_CR55","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/j.jaip.2025.07.025","volume":"13","author":"SS Saini","year":"2025","unstructured":"Saini SS, Asero R, Cugno M, Park HS, Oliver ET. Pathogenesis of chronic spontaneous urticaria with or without angioedema. J Allergy Clin Immunol Pract. 2025;13(9):2221\u20138. https:\/\/doi.org\/10.1016\/j.jaip.2025.07.025.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"1255_CR56","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.clinthera.2020.03.010","volume":"42","author":"GN Konstantinou","year":"2020","unstructured":"Konstantinou GN, Konstantinou GN. Psychological stress and chronic urticaria: A Neuro-immuno-cutaneous Crosstalk. A systematic review of the existing evidence. Clin Ther. 2020;42(5):771\u201382. https:\/\/doi.org\/10.1016\/j.clinthera.2020.03.010.","journal-title":"Clin Ther"},{"issue":"1","key":"1255_CR57","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/imr.12622","volume":"282","author":"K Gupta","year":"2018","unstructured":"Gupta K, Harvima IT. Mast cell-neural interactions contribute to pain and itch. Immunol Rev. 2018;282(1):168\u201387. https:\/\/doi.org\/10.1111\/imr.12622.","journal-title":"Immunol Rev"},{"issue":"8","key":"1255_CR58","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s13555-023-00972-6","volume":"13","author":"G Yosipovitch","year":"2023","unstructured":"Yosipovitch G, Biazus Soares G, Mahmoud O. Current and emerging therapies for chronic spontaneous urticaria: A narrative review. Dermatol Ther (Heidelb). 2023;13(8):1647\u201360. https:\/\/doi.org\/10.1007\/s13555-023-00972-6.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1255_CR59","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","volume":"29","author":"G Yosipovitch","year":"2023","unstructured":"Yosipovitch G, Mollanazar N, St\u00e4nder S, Kwatra SG, Kim BS, Laws E, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med. 2023;29(5):1180\u201390. https:\/\/doi.org\/10.1038\/s41591-023-02320-9.","journal-title":"Nat Med"},{"issue":"12","key":"1255_CR60","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","volume":"388","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Guttman-Yassky E, Tha\u00e7i D, Irvine AD, Stein Gold L, Blauvelt A, et al. Two phase 3 trials of lebrikizumab for Moderate-to-Severe atopic dermatitis. N Engl J Med. 2023;388(12):1080\u201391. https:\/\/doi.org\/10.1056\/NEJMoa2206714.","journal-title":"N Engl J Med"},{"issue":"S1","key":"1255_CR61","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1089\/derm.2023.0261","volume":"35","author":"L Potestio","year":"2024","unstructured":"Potestio L, Patruno C, Napolitano M. Efficacy and safety of tralokinumab in real life: possible predictive rapid response factors. Dermatitis. 2024;35(S1):S77\u201380. https:\/\/doi.org\/10.1089\/derm.2023.0261.","journal-title":"Dermatitis"},{"issue":"9","key":"1255_CR62","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1001\/jamadermatol.2024.2192","volume":"160","author":"AM Drucker","year":"2024","unstructured":"Drucker AM, Lam M, Prieto-Merino D, Malek R, Ellis AG, Yiu ZZN, et al. Systemic Immunomodulatory treatments for atopic dermatitis: living systematic review and network Meta-Analysis update. JAMA Dermatology. 2024;160(9):936\u201344. https:\/\/doi.org\/10.1001\/jamadermatol.2024.2192.","journal-title":"JAMA Dermatology"},{"issue":"17","key":"1255_CR63","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","volume":"389","author":"SG Kwatra","year":"2023","unstructured":"Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, et al. Phase 3 trial of Nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023;389(17):1579\u201389. https:\/\/doi.org\/10.1056\/NEJMoa2301333.","journal-title":"N Engl J Med"},{"key":"1255_CR64","doi-asserted-by":"publisher","unstructured":"L\u00e9 AM, Torres T. OX40-OX40L Inhibition for the treatment of atopic Dermatitis-Focus on rocatinlimab and amlitelimab. Pharmaceutics. 2022;14(12). https:\/\/doi.org\/10.3390\/pharmaceutics14122753.","DOI":"10.3390\/pharmaceutics14122753"},{"issue":"4","key":"1255_CR65","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","volume":"80","author":"EL Simpson","year":"2019","unstructured":"Simpson EL, Parnes JR, She D, Crouch S, Rees W, Mo M, et al. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial. J Am Acad Dermatol. 2019;80(4):1013\u201321. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.059.","journal-title":"J Am Acad Dermatol"},{"key":"1255_CR66","doi-asserted-by":"publisher","unstructured":"Chen YL, Gutowska-Owsiak D, Hardman CS, Westmoreland M, MacKenzie T, Cifuentes L, et al. Proof-of-concept clinical trial of Etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis. Sci Transl Med. 2019;11(515). https:\/\/doi.org\/10.1126\/scitranslmed.aax2945.","DOI":"10.1126\/scitranslmed.aax2945"},{"issue":"11","key":"1255_CR67","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s40265-024-02095-4","volume":"84","author":"JM Alvarenga","year":"2024","unstructured":"Alvarenga JM, Bieber T, Torres T. Emerging biologic therapies for the treatment of atopic dermatitis. Drugs. 2024;84(11):1379\u201394. https:\/\/doi.org\/10.1007\/s40265-024-02095-4.","journal-title":"Drugs"},{"issue":"6","key":"1255_CR68","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/13543784.2024.2347294","volume":"33","author":"A Tsiogka","year":"2024","unstructured":"Tsiogka A, Paschou E, Koumaki D, Vakirlis E, Gregoriou S. Interleukin antagonists for atopic dermatitis: a new era of therapy. Expert Opin Investig Drugs. 2024;33(6):549\u201359. https:\/\/doi.org\/10.1080\/13543784.2024.2347294.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"1255_CR69","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40257-023-00818-z","volume":"25","author":"S M\u00fcller","year":"2024","unstructured":"M\u00fcller S, Zeidler C, St\u00e4nder S. Chronic prurigo including prurigo nodularis: new insights and treatments. Am J Clin Dermatol. 2024;25(1):15\u201333. https:\/\/doi.org\/10.1007\/s40257-023-00818-z.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1255_CR70","doi-asserted-by":"publisher","first-page":"100258","DOI":"10.1016\/j.xjidi.2024.100258","volume":"4","author":"J Tietz","year":"2024","unstructured":"Tietz J, Gunde T, Warmuth S, Weinert C, Brock M, Simonin A, et al. A Bispecific, tetravalent antibody targeting inflammatory and pruritogenic pathways in atopic dermatitis. JID Innovations. 2024;4(2):100258. https:\/\/doi.org\/10.1016\/j.xjidi.2024.100258.","journal-title":"JID Innovations"},{"issue":"1","key":"1255_CR71","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/abt\/tbad032","volume":"7","author":"F Deng","year":"2024","unstructured":"Deng F, Qiu Y, Zhang X, Guo N, Hu J, Yang W, et al. GB12-09, a bispecific antibody targeting IL4R\u03b1 and IL31R\u03b1 for atopic dermatitis therapy. Antib Ther. 2024;7(1):77\u201387. https:\/\/doi.org\/10.1093\/abt\/tbad032.","journal-title":"Antib Ther"},{"issue":"6","key":"1255_CR72","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.jaad.2016.07.034","volume":"75","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Luger T, Gottlieb A, Puig L, Kaufmann R, Nika\u00ef E, et al. Impact of Ixekizumab on psoriasis itch severity and other psoriasis symptoms: results from 3 phase III psoriasis clinical trials. J Am Acad Dermatol. 2016;75(6):1156\u201361. https:\/\/doi.org\/10.1016\/j.jaad.2016.07.034.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1255_CR73","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s13555-018-0267-9","volume":"8","author":"G Yosipovitch","year":"2018","unstructured":"Yosipovitch G, Reich A, Steinhoff M, Beselin A, Kent T, Dossenbach M, et al. Impact of Ixekizumab treatment on itch and psoriasis area and severity index in patients with Moderate-to-Severe plaque psoriasis: an integrated analysis of two phase III randomized studies. Dermatol Ther (Heidelb). 2018;8(4):621\u201337. https:\/\/doi.org\/10.1007\/s13555-018-0267-9.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"9","key":"1255_CR74","doi-asserted-by":"publisher","first-page":"820","DOI":"10.2340\/00015555-3195","volume":"99","author":"G Yosipovitch","year":"2019","unstructured":"Yosipovitch G, Soung J, Weiss J, Muscianisi E, Meng X, Gilloteau I, et al. Secukinumab provides rapid relief from itching and pain in patients with Moderate-to-Severe psoriasis: patient symptom diary data from two phase 3, Randomized, Placebo-controlled clinical trials. Acta Derm Venereol. 2019;99(9):820\u20131. https:\/\/doi.org\/10.2340\/00015555-3195.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"1255_CR75","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40257-024-00853-4","volume":"25","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Gooderham MJ, Paller AS, Deleuran M, Bunick CG, Gold LFS, et al. Early and sustained improvements in symptoms and quality of life with upadacitinib in adults and adolescents with Moderate-to-Severe atopic dermatitis: 52-Week results from two phase III randomized clinical trials (Measure up 1 and measure up 2). Am J Clin Dermatol. 2024;25(3):485\u201396. https:\/\/doi.org\/10.1007\/s40257-024-00853-4.","journal-title":"Am J Clin Dermatol"},{"issue":"16","key":"1255_CR76","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.2217\/imt-2023-0057","volume":"15","author":"AM L\u00e9","year":"2023","unstructured":"L\u00e9 AM, Gooderham M, Torres T. Abrocitinib for the treatment of atopic dermatitis. Immunotherapy. 2023;15(16):1351\u201362. https:\/\/doi.org\/10.2217\/imt-2023-0057.","journal-title":"Immunotherapy"},{"issue":"4","key":"1255_CR77","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","volume":"85","author":"K Papp","year":"2021","unstructured":"Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DYM, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863\u201372. https:\/\/doi.org\/10.1016\/j.jaad.2021.04.085.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1255_CR78","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/all.15585","volume":"78","author":"D Terhorst-Molawi","year":"2023","unstructured":"Terhorst-Molawi D, Hawro T, Grekowitz E, Kiefer L, Merchant K, Alvarado D, et al. Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. Allergy. 2023;78(5):1269\u201379. https:\/\/doi.org\/10.1111\/all.15585.","journal-title":"Allergy"},{"issue":"1","key":"1255_CR79","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/14712598.2021.1958777","volume":"22","author":"S M\u00fcller","year":"2022","unstructured":"M\u00fcller S, Bieber T, St\u00e4nder S. Therapeutic potential of biologics in prurigo nodularis. Expert Opin Biol Ther. 2022;22(1):47\u201358. https:\/\/doi.org\/10.1080\/14712598.2021.1958777.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"1255_CR80","doi-asserted-by":"publisher","first-page":"107472","DOI":"10.1016\/j.celrep.2020.03.036","volume":"31","author":"SK Mishra","year":"2020","unstructured":"Mishra SK, Wheeler JJ, Pitake S, Ding H, Jiang C, Fukuyama T, et al. Periostin activation of integrin receptors on sensory neurons induces allergic itch. Cell Rep. 2020;31(1):107472. https:\/\/doi.org\/10.1016\/j.celrep.2020.03.036.","journal-title":"Cell Rep"},{"issue":"5","key":"1255_CR81","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.immuni.2019.03.013","volume":"50","author":"J Meixiong","year":"2019","unstructured":"Meixiong J, et al. Activation of Mast-Cell-Expressed Mas-Related G-Protein-Coupled receptors drives Non-histaminergic itch. Immunity. 2019;50(5):1163\u2013e11715.","journal-title":"Immunity"},{"issue":"4","key":"1255_CR82","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.jaci.2024.07.002","volume":"154","author":"J Wollam","year":"2024","unstructured":"Wollam J, Solomon M, Villescaz C, Lanier M, Evans S, Bacon C, et al. Inhibition of mast cell degranulation by novel small molecule MRGPRX2 antagonists. J Allergy Clin Immunol. 2024;154(4):1033\u201343. https:\/\/doi.org\/10.1016\/j.jaci.2024.07.002.","journal-title":"J Allergy Clin Immunol"},{"key":"1255_CR83","doi-asserted-by":"publisher","first-page":"1433982","DOI":"10.3389\/fimmu.2024.1433982","volume":"15","author":"CH Macphee","year":"2024","unstructured":"Macphee CH, Dong X, Peng Q, Paone DV, Skov PS, Baumann K, et al. Pharmacological Blockade of the mast cell MRGPRX2 receptor supports investigation of its relevance in skin disorders. Front Immunol. 2024;15:1433982. https:\/\/doi.org\/10.3389\/fimmu.2024.1433982.","journal-title":"Front Immunol"},{"issue":"3","key":"1255_CR84","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jaci.2016.04.051","volume":"138","author":"H Subramanian","year":"2016","unstructured":"Subramanian H, Gupta K, Ali H. Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases. J Allergy Clin Immunol. 2016;138(3):700\u201310. https:\/\/doi.org\/10.1016\/j.jaci.2016.04.051.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1255_CR85","doi-asserted-by":"publisher","first-page":"e372","DOI":"10.1111\/jdv.20338","volume":"39","author":"LF Andrade","year":"2025","unstructured":"Andrade LF, et al. B-type natriuretic peptide levels are associated with chronic itch: A case-control study. J Eur Acad Dermatol Venereol. 2025;39(4):e372\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1255_CR86","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.jaad.2019.01.052","volume":"80","author":"S St\u00e4nder","year":"2019","unstructured":"St\u00e4nder S, Kwon P, Hirman J, Perlman AJ, Weisshaar E, Metz M, et al. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial. J Am Acad Dermatol. 2019;80(5):1395\u2013402. https:\/\/doi.org\/10.1016\/j.jaad.2019.01.052.","journal-title":"J Am Acad Dermatol"},{"key":"1255_CR87","doi-asserted-by":"publisher","first-page":"4790810","DOI":"10.1155\/2017\/4790810","volume":"2017","author":"A He","year":"2017","unstructured":"He A, Alhariri JM, Sweren RJ, Kwatra MM, Kwatra SG. Aprepitant for the treatment of chronic refractory pruritus. Biomed Res Int. 2017;2017:4790810. https:\/\/doi.org\/10.1155\/2017\/4790810.","journal-title":"Biomed Res Int"},{"issue":"2","key":"1255_CR88","doi-asserted-by":"publisher","first-page":"adv00027","DOI":"10.2340\/00015555-3347","volume":"100","author":"E Fowler","year":"2020","unstructured":"Fowler E, Yosipovitch G. A new generation of treatments for itch. Acta Derm Venereol. 2020;100(2):adv00027. https:\/\/doi.org\/10.2340\/00015555-3347.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"1255_CR89","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/bph.14952","volume":"177","author":"J Meng","year":"2020","unstructured":"Meng J, Chen W, Wang J. Interventions in the B-type natriuretic peptide signalling pathway as a means of controlling chronic itch. Br J Pharmacol. 2020;177(5):1025\u201340. https:\/\/doi.org\/10.1111\/bph.14952.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"1255_CR90","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jid.2023.09.273","volume":"144","author":"JJ Wheeler","year":"2024","unstructured":"Wheeler JJ, Williams N, Yu J, Mishra SK. Brain natriuretic peptide exerts inflammation and peripheral itch in a mouse model of atopic dermatitis. J Invest Dermatol. 2024;144(3):705\u20137. https:\/\/doi.org\/10.1016\/j.jid.2023.09.273.","journal-title":"J Invest Dermatol"},{"key":"1255_CR91","doi-asserted-by":"publisher","unstructured":"Wang F, Trier AM, Li F, Kim S, Chen Z, Chai JN et al. A basophil-neuronal axis promotes itch. Cell. 2021;184(2):422\u2009\u2013\u200940.e17. https:\/\/doi.org\/10.1016\/j.cell.2020.12.033","DOI":"10.1016\/j.cell.2020.12.033"},{"issue":"1","key":"1255_CR92","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nn.3881","volume":"18","author":"D Usoskin","year":"2015","unstructured":"Usoskin D, Furlan A, Islam S, Abdo H, L\u00f6nnerberg P, Lou D, et al. Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing. Nat Neurosci. 2015;18(1):145\u201353. https:\/\/doi.org\/10.1038\/nn.3881.","journal-title":"Nat Neurosci"},{"key":"1255_CR93","doi-asserted-by":"publisher","first-page":"1162049","DOI":"10.3389\/fnana.2023.1162049","volume":"17","author":"K Xie","year":"2023","unstructured":"Xie K, Cheng X, Zhu T, Zhang D. Single-cell transcriptomic profiling of dorsal root ganglion: an overview. Front Neuroanat. 2023;17:1162049. https:\/\/doi.org\/10.3389\/fnana.2023.1162049.","journal-title":"Front Neuroanat"},{"issue":"1","key":"1255_CR94","doi-asserted-by":"publisher","first-page":"7729","DOI":"10.1038\/s41467-022-35319-w","volume":"13","author":"A Sch\u00e4bitz","year":"2022","unstructured":"Sch\u00e4bitz A, Hillig C, Mubarak M, Jargosch M, Farnoud A, Scala E, et al. Spatial transcriptomics landscape of lesions from non-communicable inflammatory skin diseases. Nat Commun. 2022;13(1):7729. https:\/\/doi.org\/10.1038\/s41467-022-35319-w.","journal-title":"Nat Commun"},{"issue":"4","key":"1255_CR95","doi-asserted-by":"publisher","first-page":"100198","DOI":"10.1016\/j.xjidi.2023.100198","volume":"3","author":"AE Houser","year":"2023","unstructured":"Houser AE, Kazmi A, Nair AK, Ji AL. The use of Single-Cell RNA-Sequencing and Spatial transcriptomics in Understanding the pathogenesis and treatment of skin diseases. JID Innov. 2023;3(4):100198. https:\/\/doi.org\/10.1016\/j.xjidi.2023.100198.","journal-title":"JID Innov"},{"issue":"4","key":"1255_CR96","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/s41592-025-02610-9","volume":"22","author":"T Kagan","year":"2025","unstructured":"Kagan T, Gabay M, Meenakshisundaram A, Levi Y, Eid S, Malchenko N, et al. Genetically encoded biosensor for fluorescence lifetime imaging of PTEN dynamics in the intact brain. Nat Methods. 2025;22(4):764\u201377. https:\/\/doi.org\/10.1038\/s41592-025-02610-9.","journal-title":"Nat Methods"},{"issue":"9","key":"1255_CR97","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.tibs.2025.05.006","volume":"50","author":"T Kagan","year":"2025","unstructured":"Kagan T, Laviv T. Biosensor for monitoring PTEN activity in biological systems. Trends Biochem Sci. 2025;50(9):834\u20135. https:\/\/doi.org\/10.1016\/j.tibs.2025.05.006.","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"1255_CR98","doi-asserted-by":"publisher","first-page":"10688","DOI":"10.1038\/s41467-024-54559-6","volume":"15","author":"T Seremet","year":"2024","unstructured":"Seremet T, Di Domizio J, Girardin A, Yatim A, Jenelten R, Messina F, et al. Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseases. Nat Commun. 2024;15(1):10688. https:\/\/doi.org\/10.1038\/s41467-024-54559-6.","journal-title":"Nat Commun"},{"issue":"1","key":"1255_CR99","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13620-021-00184-4","volume":"74","author":"T Kamalikhah","year":"2021","unstructured":"Kamalikhah T, Mirrezaei S, Rahimi T, Sabzmakan L, Ghobakhloo S. Community readiness for collecting stray dogs in Aradan county: a quantitative-qualitative study. Ir Vet J. 2021;74(1):10. https:\/\/doi.org\/10.1186\/s13620-021-00184-4.","journal-title":"Ir Vet J"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-026-01255-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-026-01255-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-026-01255-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:29:51Z","timestamp":1781634591000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-026-01255-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1255"],"URL":"https:\/\/doi.org\/10.1007\/s11882-026-01255-8","relation":{},"ISSN":["1534-6315"],"issn-type":[{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Gil Yosipovitch serves as an advisory board member for Arcutis Biotherapeutics, AbbVie, Eli Lilly, Galderma, GSK, Kiniksa Pharmaceuticals, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc, Sanofi, Escient, and Merck Vifor. Dr. Gil Yosipovitch receives grants\/research funding from Regeneron Pharmaceuticals, Inc and Sanofi. Dr. Gil Yosipovitch is an investigator for Pfizer, Eli Lilly, Novartis, Escient, and Sanofi. Nicole Khalil and Tomer Kagan have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Dr. Gil Yosipovitch serves as an advisory board member for Arcutis Biotherapeutics, AbbVie, Eli Lilly, Galderma, GSK, Kiniksa Pharmaceuticals, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc, Sanofi, Escient, and Merck Vifor. Dr. Gil Yosipovitch receives grants\/research funding from Regeneron Pharmaceuticals, Inc and Sanofi. Dr. Gil Yosipovitch is an investigator for Pfizer, Eli Lilly, Novartis, Escient, and Sanofi. Nicole Khalil and Tomer Kagan have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"This study does not contain any studies with human or animal subjects performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}}],"article-number":"12"}}